Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,189,759

-0.15 (-0.67%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

by Zacks Equity Research

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1

by Zacks Equity Research

Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.

Exelixis (EXEL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 12.50% and 5.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ProQR Initiates Dosing in Phase II/III Eye Disorder Study

by Zacks Equity Research

ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?

by Zacks Equity Research

Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.

The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

Tirthankar Chakraborty headshot

Biotech Stocks Outperform During Inversions: 5 Must Watch

by Tirthankar Chakraborty

An inverted yield curve signals a recession but it is often bullish for biotech stocks.

Exelixis (EXEL) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Exelixis (EXEL) closed at $24.76 in the latest trading session, marking a +0.2% move from the prior day.

Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation

by Zacks Equity Research

Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.

Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Exelixis (EXEL) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day.

New Strong Sell Stocks for February 15th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Implied Volatility Surging for Exelixis (EXEL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.

Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4

by Zacks Equity Research

Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.

Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Exelixis (EXEL) closed at $22.60, marking a -0.96% move from the previous day.

Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

by Zacks Equity Research

Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 17th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

by Zacks Equity Research

Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

by Zacks Equity Research

Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Exelixis (EXEL) closed at $23.76, marking a -1.29% move from the previous day.